Unknown

Dataset Information

Aprotinin in high-risk isolated coronary artery bypass graft patients: a 3-year propensity matched study.


ABSTRACT:

Background

Aprotinin, a serine protease inhibitor, has been used variably in cardiac surgery amidst ongoing debates about its safety following several previous studies. This study assesses the outcomes of aprotinin in high-risk isolated Coronary Artery Bypass Graft (iCABG) patients.

Methods

The study retrospectively analysed a cohort of 1026 iCABG patients, including 51 patients who underwent aprotinin treatment. Logistic regression powered score matching was employed to compare aprotinin patients with a control group, in a propensity-matched cohort of 96 patients. The primary outcome measured was in-hospital death, with secondary outcomes including renal dysfunction, stroke, myocardial infarction, re-exploration for bleeding or tamponade, and postoperative stay durations.

SUBMITTER: Makam R 

PROVIDER: S-EPMC11256430 | biostudies-literature | 2024 Jul

REPOSITORIES: biostudies-literature